Functional and Morphological Cardiac Changes in Myeloproliferative Neoplasms
试验速览
- 阶段
- 不适用
- 入组人数
- 40
- 主要终点
- number of patients with cardiac complications in myeloproliferative diseases.
研究概览
简要总结
Myeloproliferative neoplasms are heterogeneous group of clonal hematopoietic stem cell neoplasms with excessive proliferation of one or more of the erythroid, megakaryocytic, or myeloid lineages and relatively normal maturation resulting in increased numbers of red cells, platelets, and/or granulocytes in the peripheral blood. Constitutive tyrosine kinase activation appears to be a common pathogenetic mechanism.
详细描述
According to worldwide study of prevalence of myeloproliferative neoplasms revealed:
Incidence of polycythemia vera ranged 0.01 to 2.61 per 100.000 population and the prevalence ranging from 0.49 to 46.88 per 100.000 population. Incidence of essential thrombocythemia is 0.21 to 2.27 per 100.000 population, prevalence ranging between 11.00 - 42.51 per 100.000 population.
Primary myelofibrosis incidence is 1.15 -4.99 per 100.000 population and prevalence ranging between 1.76 - 4.05 per 100.000 population.In previous studies, cardiac involvement including coronary arterial thrombosis, myocardial infarction, pulmonary hypertension, asymptomatic pericardial effusion, cardiac tamponade, intractable cardiac failure due to intraventricular stenosis and valvular stenosis that occur in myeloproliferative neoplasms. There is a few number of studies in which cardiac lesions were evaluated in myeloproliferative neoplasms by using transthoracic echocardiography but still inadequate, so we need to understand more about cardiovascular complications in myeloproliferative neoplasms.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Diagnostic criteria of myeloproliferative neoplasms.
排除标准
- •Extreme body weight e.g., morbid obesity.
- •Cardiac disease.
- •Cerebrovascular disorders.
- •Diabetes mellitus.
- •Dyslipidemia.
结局指标
主要结局
number of patients with cardiac complications in myeloproliferative diseases.
时间窗: 30 minutes
cardiac complications as valvular changes, ejection fraction changes, pulmonary hypertension
次要结局
未报告次要终点
研究者
AKAli
principal investigator
Assiut University